We compared the effects of treating SCD patient CD34+ HSPCs with ABE7.10 or ABE8e RNP to install γ-globin −175 or with Cas9 RNP to disrupt the γ-globin promoter BCL11A binding site. The gene discussed is CD34; the disease is Schnyder corneal dystrophy.